Menlo Therapeutics Inc. Uncategorized Contracts & Agreements

23 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Letter Agreement, dated as of February 27, 2023, by and between VYNE Therapeutics Inc. and Tay Therapeutics Ltd
Menlo Therapeutics Inc.
Pharmaceuticals
2023
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
Menlo Therapeutics Inc.
Pharmaceuticals
2023
Letter Agreement, dated as of June 15, 2022, by and between VYNE Therapeutics Inc. and In4Derm Limited
Menlo Therapeutics Inc.
Pharmaceuticals
2022
Offer Letter, dated as of March 15, 2022, by and between VYNE Pharmaceuticals Inc. and Tyler Zeronda
Menlo Therapeutics Inc.
Pharmaceuticals
2022
Offer Letter, dated as of March 7, 2022, by and between VYNE Pharmaceuticals Inc. and Iain Stuart
Menlo Therapeutics Inc.
Pharmaceuticals
2022
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
Menlo Therapeutics Inc.
Pharmaceuticals
2022
Evaluation and Option Agreement, dated as of April 30, 2021, by and between In4Derm Limited and VYNE Therapeutics Inc
Menlo Therapeutics Inc.
Pharmaceuticals
2021
Offer Letter, dated as of June 7, 2021, by and between Tyler Zeronda and VYNE Pharmaceuticals Inc
Menlo Therapeutics Inc.
Pharmaceuticals
NJ
2021
Offer Letter, dated as of April 7, 2021, by and between Mutya Harsch and VYNE Pharmaceuticals Inc
Menlo Therapeutics Inc.
Pharmaceuticals
2021
Offer Letter, dated as of April 7, 2021, by and between Andrew Saik and VYNE Pharmaceuticals Inc
Menlo Therapeutics Inc.
Pharmaceuticals
2021
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
Menlo Therapeutics Inc.
Pharmaceuticals
2021
Offer Letter, dated as of March 20, 2020, by and between Menlo Therapeutics Inc. and Andrew Saik
Menlo Therapeutics Inc.
Pharmaceuticals
NJ
2020
Offer Letter, dated as of March 25, 2020, by and between Menlo Therapeutics Inc. and David Domzalski
Menlo Therapeutics Inc.
Pharmaceuticals
NJ
2020
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
Menlo Therapeutics Inc.
Pharmaceuticals
2020
Form of CSR Agreement
Menlo Therapeutics Inc.
Pharmaceuticals
DE
2019
Amendment No. 1 to Offer Letter, by and between the Registrant and Mary Spellman, effective as of April 22, 2018
Menlo Therapeutics Inc.
Pharmaceuticals
2018
Offer Letter, by and between the Registrant and Mary Spellman, effective as of July 21, 2017
Menlo Therapeutics Inc.
Pharmaceuticals
2018
Amendment No. 1 to Offer Letter, by and between the Company and Paul Kwon, effective as of May 3, 2018
Menlo Therapeutics Inc.
Pharmaceuticals
2018
Amendment No. 1 to Offer Letter, by and between the Company and Kristine Ball, effective as of May 3, 2018
Menlo Therapeutics Inc.
Pharmaceuticals
2018
Amendment No. 1 to Offer Letter, by and between the Company and Steven Basta, effective as of May 3, 2018
Menlo Therapeutics Inc.
Pharmaceuticals
2018
Offer Letter, dated as of August 15, 2017 by and between the Company and Kristine Ball
Menlo Therapeutics Inc.
Pharmaceuticals
2017
Offer Letter, dated as of January 14, 2016 by and between the Company and Paul Kwon
Menlo Therapeutics Inc.
Pharmaceuticals
2017
Offer Letter, dated as of August 17, 2015 by and between the Company and Steven Basta
Menlo Therapeutics Inc.
Pharmaceuticals
2017